Björn Dahlbäck is professor of Blood Coagulation Research at Lund University, Department of Laboratory Medicine, Skåne University Hospital, Malmö, Sweden. His research on the molecular mechanisms of the protein C anticoagulant system has focused on the role of activated protein C and its cofactor protein S in the degradation of coagulation factors V and VIII. Observations made during these studies lead into studies of other biologically important host defense systems, in particular the complement system, and the interactions between the coagulation and complement systems. He described that protein S in blood circulates both as free protein and bound to the complement regulatory protein C4b-binding protein (C4BP) and demonstrated that analysis of free protein S is the method of choice to detect inherited protein S deficiency. He has also been interested in the genetics of thrombophilia and described APC resistance, caused by FV Leiden as the major inherited risk factor of thrombosis. Recently, he was involved in the elucidation of a mysterious autosomal dominant bleeding disorder from East Texas. The disease is caused by a point mutation in factor V, which induces alternative splicing and the creation of a short form of FV that causes the bleeding tendency via tissue factor pathway inhibitor (TFPI). Björn Dahlbäck is member of the ISTH Council, the Swedish Royal Academy of Science, and honorary member of the American Society of Hematology. He has published 305 original papers and 99 reviews, has been cited approx. 22,000 times and has an H-index of 75. He has received many awards for his research.
Sabine Eichinger is Associate Professor of Medicine at the Medical University of Vienna, Austria, and Head of the Anticoagulation Clinic at the Department of Medicine I of the Medical University Hospital in Vienna. Dr. Eichinger received her medical and scientific training at the Department of Medicine I, Division of Haematology and Haemostasis, University of Vienna, and at the Beth Israel Hospital, Harvard Medical School, Boston, USA.
Dr. Eichinger’s anticoagulation research has included investigating the mechanism of action of pro-coagulants and anticoagulants in in vitro and in vivo models, and the pathophysiology of the coagulation system in women. She has undertaken research to evaluate the risk factors for thrombotic disease and biomarkers of the coagulation system. In 1992, she initiated one of the world’s largest studies in patients with venous thrombosis, the Austrian Study on Recurrent Venous Thromboembolism. She is the local principal investigator of several interventional studies in patients with venous thromboembolism and atrial fibrillation, and an internationally recognised expert in designing and conducting clinical studies. She is Chair-elect of the Scientific and Standardization Subcommittee(SSC) of the ISTH, and is the recipient of several academic awards.
Dr. Christian Gachet graduated as a medical doctor in 1985 and gained his Ph.D. in Pharmacology in 1991, both at the Université Louis Pasteur, Strasbourg, France. He became a Research Director at INSERM (Institut National de la Santé et de la Recherche Médicale) in 1998. Dr. Gachet is currently the Director of the INSERM Research Unit 949 and the Scientific Director at Etablissement Français du Sang-Alsace.
The focus of Dr. Gachet’s work has long been the molecular mechanisms of ADP-induced platelet activation and its inhibition by the thienopyridine compounds. This led to the characterization and the identification of some of the platelet P2 receptors. He carried out extensive work on the P2Y1 platelet receptor and the P2X1 receptor. Dr. Gachet’s current interest is in general platelet physiology (formation of blood platelets, megakaryopoiesis, platelet activation) and pharmacology (new drugs, new targets), animal models of platelet defects (BSS, MYH9, P2 receptors), mouse models of arterial thrombosis in a context of atherosclerosis and clinical studies on the variability of the response to clopidogrel. Dr. Gachet has published over 200 papers in peer-reviewed journals and over 300 communications in his area of expertise. He also serves on the editorial boards of the Journal of Thrombosis and Haemostasis(JTH). Dr. Gachet has received several distinctions for his work in the field of atherothrombosis.
Andreas Greinacher is an M.D. with a specialization in transfusion medicine and hemostasis. His scientific career is focused on platelet disorders, bridging immuno-hematology and hemostasis. He is working at the University Hospital Greifswald, Germany, where he is head of the Institute of Immunology and Transfusion Medicine, the clinical thrombosis and hemostasis service, the hemostasis out-patient clinic, the transfusion and stem cell service and the immuno-hematology laboratory. Aside from heparin-induced thrombocytopenia and drug dependent thrombocytopenia, he has a major interest in hereditary and acquired platelet disorders. His recent work is focusing on adopting nanotechnology and biophysical methods to investigate platelets and protein changes. He is section editor of several journals in the field of thrombosis and hemostasis and the current chairman of the education committee of the ISTH.
Phillip G. de Groot is a professor of Biochemistry appointed at the University Hospital in Utrecht, the Netherlands. Presently, he is deputy head of the department of Clinical Chemistry and Haematology. Besides his responsibility for laboratory diagnostics, particularly in the field of haematology, he has run a research group on thrombosis and haemostasis for over 30 years. He has published over 400 peer-reviewed articles and has a Hirsch index of 66. This year he was awarded with the biennial Distinguished Career Award of the ISTH. One of the major interests of his laboratory is to understand why the presence of antiphospholipid antibodies increases the risk on thrombosis. Their approach to this problem was twofold; they aim to develop assays available that identify the subpopulation of antiphospholipid antibodies responsible for the thrombotic risk and, secondly, to understand the physiological function of the major antigen in this syndrome, b2-glycoprotein I. If they understand the protein, they will understand why antibodies directed against this protein are one of the most common acquired risk factors for thrombosis and pregnancy morbidity.
David Lillicrap, M.D., FRCPC
Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, Kingston, Canada. Since 2000, he has been the recipient of a Canada Research Chair in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. He has served on the Gene Therapy Working Group of the US National Hemophilia Foundation (NHF) and has been a member of NHF’s Medical and Scientific Advisory Committee. He is the Chair of the Research Committee of the World Federation of Hemophilia (WFH) and is a member of the Medical Advisory Board of the WFH. He recently completed a three-year term as the chairperson of the ISTH's SSC Subcommittee on von Willebrand Factor, and is the current Chair of the Society’s SSC. He is an Associate Editor of the journal Blood, and a member of the editorial board of the British Journal of Haematology. His research program relates to molecular aspects of the hemostatic system with particular emphasis on novel therapeutic approaches and immunological complications of hemophilia A, and the genetics, biology and pathobiology of von Willebrand Factor.
Bernd Poetzsch received his medical education at Justus-Liebig-University in Giessen, Germany, 1981 - 1988 and his postgraduate training at the Heart Centre Kerckhoff-Clinik in Bad Nauheim, Germany. Since 1999 he is a full-term professor and senior physician at the University of Bonn, Germany, specialized in hemostasis and thrombosis. His focus of research is pathogenesis, diagnosis and treatment of thrombophilia and use of aptamers in diagnosis and treatment of coagulation disorders.
Sam Schulman graduated from Karolinska Institute, Stockholm, Sweden in 1977 and became a specialist in Internal Medicine in 1984, with subspecialties in Haematology and in Coagulation in 1985. That year he also received his Dr Med Sc with the thesis: "Studies on the Medical Treatment of Deep Vein Thrombosis." He has worked within the field of coagulation disorders continuously since 1984, worked as a consultant at the national Hemophilia Center at Tel Hashomer, Israel from 1992-1996, and was director of the Hemophilia Treatment Center in Stockholm from 1996-2004. His major research activities have been clinical studies in venous thromboembolism, including several randomized trials and in hemophilia and its complications. He is currently involved in trials with new antithrombotic agents, such as the oral thrombin inhibitors. He has been a member of the Executive Committee of the World Federation of Hemophilia (2000-2004) and was chairman of the Subcommittee on Control of Anticoagulation of the SSC Subcommittee of ISTH from 2005-2008. Dr. Schulman is associate professor in Internal Medicine at Karolinska Institute and since September 2004 also a professor in Medicine at McMaster University. He is Director of the Thrombosis Service at HHS-General Hospital in Hamilton and Director of the Clinical Thromboembolism Program of McMaster University.
Theodore E. Warkentin, M.D., is a Professor in the Department of Medicine and the Department of Pathology and Molecular Medicine at the Michael G. DeGroote School of Medicine, McMaster University, in Hamilton, Ontario, Canada. He is also Regional Director, Transfusion Medicine, of the Hamilton Regional Laboratory Medicine Program and Hematologist, Service of Clinical Hematology, at Hamilton Health Sciences, also in Hamilton. Dr. Warkentin received both his Bachelor of Science (in Medicine) and his M.D. from the University of Manitoba in Winnipeg, Manitoba, Canada. He completed a hematology research fellowship at McMaster University and postgraduate work in medicine and hematology at the University of Toronto and McMaster University, respectively. He was awarded the XVth Jean Julliard Prize at the XXIVth Congress of the International Society of Blood Transfusion (Makuhari, Japan; in 1996) and was a Research Scholar of the Heart and Stroke Foundation of Canada from 1993 to 1998. Dr Warkentin is the former Chair (four-year term ending 2007) of the Platelet Immunology SSC Subcommittee, and was the Chair of the 2004 and 2008 consensus conference guidelines on heparin-induced thrombocytopenia, written under the aegis of the American College of Chest Physicians (ACCP).